Lv01
0 积分 2024-06-11 加入
Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide
2小时前
待确认
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
3个月前
已完结
A Review of Obesity and Body Fat Distribution and Its Relationship to Cardio-Metabolic Risk in Men and Women of Chinese Origin
3个月前
已完结
Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
3个月前
已完结
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
3个月前
已完结
Tirzepatide’s role in targeting adipose tissue macrophages to reduce obesity-related inflammation and improve insulin resistance
4个月前
已完结
皖公网安备34019202002308
